Department of Anaesthesiology, Laboratory of Anaesthesia, University of Louvain, St Luc Hospital, av. Hippocrate 101821, 1200 Brussels, Belgium
* Corresponding author. E-mail: dekock{at}anes.ucl.ac.be
Accepted for publication April 29, 2004.
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Methods. The MACbar of sevoflurane was measured in controls and in animals treated with sufentanil 0.005 µg kg1 min1 before and after administration of i.v. (0.25, 0.5 mg kg1) and intrathecal (i.t.) (250 µg) ketamine, i.v. (0.5, 1 mg kg1) and i.t. (30 µg) MK-801(NMDA antagonist), i.v. (0.1, 0.5 mg kg1) naloxone, i.v. (10 mg kg1) and i.t. (50, 100 µg) ketorolac or i.t. (100, 150 µg) meloxicam (COX-2 inhibitor).
Results. Sufentanil 0.005 µg kg1 min1 significantly increased MACbar (3.2 (SD 0.3) versus 1.9 (0.3) vol%). With the exception of naloxone, all drugs displayed a significant MACbar-sparing effect (>50%) in controls. Naloxone completely prevented haemodynamic hyperactivity. Two patterns of reaction were recorded for the other drugs: either hyper-reactivity was suppressed and the MACbar-sparing effect was maintained (i.t. ketamine, i.t. MK-801, i.t. ketorolac [100 µg], i.t. meloxicam [150 µg]) or hyper-reactivity was blocked but MACbar-sparing effect was lost (i.v. ketamine [0.5 mg kg1], i.v. MK-801 [0.5, 1 mg kg1], i.v. ketorolac [10 µg kg1], i.t. ketorolac [50 µg], i.t. meloxicam [100 µg]).
Conclusions. We have demonstrated that low-dose sufentanil-induced haemodynamic hyper-reactivity is an excitatory µ-opiate-related phenomenon. This effect is reversed by drugs effective in treating opiate-induced hyperalgesia.
Keywords: anaesthetics volatile, sevoflurane ; analgesics opioid, sufentanil ; pain, mechanisms
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Using a pharmacological approach, the present investigation intends to determine the similarities, if any, between this opiate-induced excitatory haemodynamic phenomenon unmasked by sevoflurane and the hyperalgesia consecutive to opiate administration that was observed in awake animals.4 For this purpose, several drugs known to interfere with opiate acute tolerance37 were tested to reverse this opiate-induced haemodynamic hyper-reactivity. They include the NMDA antagonists ketamine and MK801, the opiate antagonist naloxone and Cox-1, and the Cox-2 inhibitors ketorolac and meloxicam.
![]() |
Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Animals designed to receive intrathecal (i.t.) medications were implanted with chronic lumbar intrathecal catheters as described by Yaksh and Rudy.8 Briefly, rats were anaesthetized with sevoflurane and an intrathecal catheter (PE-10 tubing) was inserted through a small hole in the cisterna magnum and advanced 8 cm caudally such that the tip lay in the intrathecal space around the lumbar enlargement. The animals were allowed to recover over a period of 45 days. Rats showing neurological deficit were immediately killed by an overdose of pentobarbital. Then the correct placement of the spinal catheter was assessed by injection of lidocaine 500 µg. Animals that did not display complete motor blockade were excluded. During the study, the tests were performed between 10 a.m. and 4 p.m.
Determination of MACbarsevo (minimum alveolar concentration of sevoflurane that blocks cardiovascular response to noxious stimulus)
Sevoflurane was obtained from Abbott Laboratories (Chicago, USA). The methodology was comparable to the one used in previous work.1 Briefly, rats were placed in an induction chamber to which sevoflurane 8% in a continuous oxygen flow of 3 litre min1 was directed (Sevoflurane Vaporizer; Dräger, Lübeck, Germany). After 23 min, the inspired sevoflurane concentration was reduced to 3%. After approximately 5 min, the animals were removed from the induction chamber and positioned supine. Sevoflurane was administered via a plastic cone.
Tracheotomy was performed and a 16 gauge polyethylene catheter inserted. The correct position of the catheter was checked before it was connected to a small T-piece (minimal dead space). Fresh gas flow to the T-piece was adjusted to 1 litre min1, and sevoflurane concentration was adjusted as required by prevailing conditions. The femoral artery and vein of one hindpaw were catheterized with a fine tubing (PE-50) via surgical cutdown.
Monitoring. At the end of this surgical preparation, mechanical ventilation (modified Spiromat 650 ventilator; Dräger, Lübeck, Germany) was started with oxygen (, 100%; Vt, ±10 ml kg1; respiratory rate, 3545 bpm). Ventilation was adjusted for an end-tidal CO2 of approximately 2530 mmHg (Datex, AS3, Helsinki, Finland) and a maximum peak pressure of 25 mmHg. Arterial blood pressure via the femoral catheter connected to a pressure transducer (Edwards Lifesciences, Unterschleissheim, Germany) and electrocardiogram were continuously monitored (Datex, AS3, Helsinki, Finland). Arterial blood gases were measured at the end of the experiment to ensure that the values were within normal limits of pH (7.357.45), oxygen pressure
(>90 mmHg) and carbon dioxide pressure
(3040 mmHg). Rectal temperature was monitored and maintained between 37 and 38°C by means of heating light.
Determination of minimum alveolar concentration. Inspiratory and end-expiratory sevoflurane concentrations were continuously measured by an IR spectrometer (Datex AS3 Helsinki, Finland), calibrated before each manipulation. Samples were collected at the tip of the endotracheal canula (0.5 cm above the carina).
After every step change in anaesthetic concentration delivered by the anaesthetic circuit, an equilibration time (inspiratory sevoflurane concentration equal to end expiratory) was allowed (at least 15 min) before a new noxious stimulus was applied.
The value of the minimum alveolar concentration of sevoflurane that blocks cardiovascular response to noxious stimulus (MACbarsevo) was established according to the method described by Eger and colleagues9 and Roizen and colleagues.10 A noxious stimulus was applied with a long haemostat (8-inch Rochester Dean Hemostatic Forceps; Martin, Tuttlingen, Germany) clamped to the first ratchet lock on the tail for 30 s. The tail was always stimulated proximal to a previous test site. A 10% increase in systolic arterial blood pressure was considered a positive response. No change or a change below this threshold was considered a negative response. In all cases, measurements were started at equilibrium with 1.5 vol% sevoflurane. According to the cardiovascular response, the sevoflurane concentration was then adjusted in decrements or increments of 0.2% until the negative response became positive or the positive response became negative.
All measurements were performed in apnoea to avoid haemodynamic variations related to the different phases of mechanical ventilation.
Experimental design. Basal (predrug) MACbarsevo was determined in every animal. Rats then received drugs known to interfere with acute opiate tolerance (ketamine, MK801, naloxone, ketorolac, meloxicam) or saline 15 min after the predrug MACbarsevo measurement. A second MAC determination followed, and 15 min later the excitatory dose of sufentanil (Janssen Pharmaceutica, Beerse, Belgium) was administered. The excitatory dose of sufentanil, as assessed by a previous investigation,1 consisted of a bolus of 0.015 µg kg1 followed by a continuous infusion of 0.005 µg kg1 min1. After predrug (control group) MACbar assessment, the animals were randomly assigned to receive one of the following drugs: i.v. ketamine (0.25, 0.5 mg kg1), i.t. ketamine (250 µg), i.v. MK-801 (0.5, 1 mg kg1), i.t. MK-801 (30 µg) (dose chosen according to Ishizaki and colleagues11), i.v. naloxone (0.1, 0.5 mg kg1), i.v. ketorolac 10 mg kg1, i.t. ketorolac (50, 100 µg) or i.t. meloxicam (100, 150 µg) (Boerhinger Ingelheim, Ingelheim, Germany). Six animals were studied for each condition. MACbarsevo determination in treated animals was carried out 30 min after the previous evaluation (predug) and was performed according to the same method.
Only rats with a normal systolic arterial blood pressure (110160 mmHg) after initial instrumentation were included. During the study protocol, animals presenting with persistent low systolic arterial blood pressure (<100 mmHg not responding to 2 ml Haemacel fluid supplementation) were excluded from data analysis.
Statistical analysis
MACbarsevo for each rat was calculated as follows. During each experiment, the first change in reaction (i.e. from reaction to pain stimulus to no reaction) was registered and the mean of the two adjacent doses of sevoflurane (i.e. immediately before and immediately after the change) was taken as the MACbarsevo. The normal distribution of the data was assessed by the KolmogorovSmirnov test. Different MAC values were compared using repeated measures of analysis of variance, followed by post hoc analysis using Tukey's test. The same tests were applied for intra- and intergroup comparison of the change in systolic arterial blood pressure.
Results are presented as mean (SD), and P<0.05 was considered statistically significant.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Effects of drugs on MACbarsevo (Figs 1, 2 and 3)
With the exception of naloxone, all drugs reduced the predrug MACbarsevo. Both i.v. ketamine 0.5 mg kg1 and i.t. ketamine reduced MACbarsevo by approximately 70%. Intravenous MK-801 1 mg kg1 and i.t. MK-801 30 µg reduced MACbarsevo by approximately 40% and 76%, respectively. Of the COX inhibitors, i.t. meloxicam 150 µg was the most efficacious with a 90% reduction.
|
|
|
Intravenous naloxone 0.5 mg kg1 completely prevented the sufentanil-induced increase in MACbarsevo.
None of the drugs significantly affected systolic arterial pressure.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Non-competitive antagonists at the N-methyl-D-aspartate receptor, ketamine and MK-801 were used because the excitatory neurotransmitter glutamate plays a pivotal role in the development and maintenance of opioid-induced excitatory effects via these receptors.12 For example, ketamine has been demonstrated to prevent opioid hyperalgesia in animals and humans.35 13 In our study, the selective NMDA antagonist MK-801 was used in order to determine that the effect observed after ketamine administration is related to antagonism at the NMDA receptor. This was done because ketamine can act on several receptor systems, such as the opioidergic (µ, ,
)14 15 and cholinergic (muscarinic and nicotinic)15 systems, involves the monoaminergic system16 and shows local anaesthetic effects by blockade of the sodium channels.17 Concerning the routes of administration (i.v. versus i.t.), it is interesting to point out that whereas i.v. ketamine and MK-801 both reverse sufentanil-induced increase in MACbarsevo, their specific sevoflurane MACbar-sparing effect is lost. In contrast, i.t. ketamine and MK-801 inhibit the exacerbated haemodynamic reactivity but maintain their sevoflurane MACbar-sparing effect. This finding argues in favour of a preferential spinal site for MACbar. These data are in agreement with a previous study where we demonstrated a spinal site of action for the MACbar-sparing effect of i.v. clonidine.18 It also highlights the important role played by spinal NMDA receptors in the processing of spinal polysynaptic reflexes,19 and particularly of cardiocirculatory responses following noxious stimulation as already assessed for pain perception (wind-up phenomenon).20 21
Low doses (0.5 mg kg1) of the specific opioid antagonist naloxone are devoid of effect on the MACbarsevo whereas it totally prevents the sufentanil-induced increase in this response. Hence the recorded excitatory manifestation is mediated by opiate receptors. This observation is consistent with the work of Crain and Shen.2 Using a multidisciplinary approach based on nociceptive neurones in culture, behavioural assays in mice and clinical trials on post-surgical pain patients, these authors demonstrated a specific effect of low doses of naloxone or nalmefene on Gs-coupled excitatory opioid receptor functions together with markedly enhanced morphine antinociceptive potency and simultaneous attenuation of opioid tolerance and dependence by co-treatment with these opioid antagonists.
The results obtained with non-steroidal anti-inflammatory drugs (NSAIDs) are of particular interest. Ketorolac, the non-specific COX-1/COX-2 inhibitor, and meloxicam, the more selective COX-2 inhibitor, significantly reduced MACbarsevo in control and sufentanil-treated animals. Such an observation is not surprising. While it is clear that NSAIDs exert their analgesic effect by interacting with local inflammatory processes, strong evidence also exists for a central analgesic effect22 23 or, rather, an anti-hyperalgesic effect as previously demonstrated in animal models.24 25 Spinal administration of NSAIDs provides efficient analgesia in humans26 and an intraoperative anaesthetic-sparing effect of systemic NSAIDs has been described in surgical patients.27 A spinal interaction between cyclooxygenase and NMDA receptor activity seems to partly account for this central effect of NSAIDs7 which may explain the positive results we observed in our model on sufentanil-induced haemodynamic hyper-reactivity. It has been demonstrated that COX-2 expressed in the central nervous system colocalizes with glutamate in excitatory neurones and that NMDA receptor activation results in increased prostanoid synthesis.28
In conclusion, using a pharmacological approach, we were able to confirm the similarity between opiate-induced hyperalgesia in awake animals and an increased cardiocirculatory reactivity following a noxious stimulus in rodents under sevoflurane anaesthesia and low-dose opioid. Does the present study indicate that sevoflurane exacerbates the excitatory effects of the opiates? From a theoretical point of view, this appears unlikely because volatile anaesthetics inhibit rather than stimulate NMDA-mediated excitatory neurotransmission.29 It appears that sevoflurane exacerbates both excitatory and inhibitory effects of opiates on nociception because, in our previous study with this model,1 we observed significant MAC-sparing effects using doses of sufentanil that were completely ineffective in awake animals.
![]() |
Acknowledgments |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2 Crain SM, Shen K. Antagonists of excitatory receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 2000; 84: 12131[CrossRef][ISI][Medline]
3 Célèrier E, Laulin J, Larcher A, et al. Evidence for opiate-activated NMDA processes masking opiate analgesia in rats. Brain Res 1999; 91: 150920
4 Rivat C, Laulin JP, Corcuff JB, Celerier E, Pain L, Simonnet G. Fentanyl enhancement of carraggeenan-induced long-lasting hyperalgesia in rats: prevention by N-methyl-D-aspartate receptor antagonist ketamine. Anesthesiology 2002; 96: 38191[CrossRef][ISI][Medline]
5 Célèrier E, Rivat C, Jun Y, et al. Long -lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 2000; 92: 46572[CrossRef][ISI][Medline]
6 Crain SM, Shen K. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasks potent opioid analgesia. Brain Res 2001; 888: 7582[CrossRef][ISI][Medline]
7 Sotgiu ML, Biella G, Formaglio F, Marchettini P. Central effect of ketorolac involving NMDA receptors activity. Brain Res 1998; 30: 2236[CrossRef]
8 Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976; 7: 103236
9 Eger E II, Saidman LJ, Brandstater B. Minimum alveolar anesthetic concentration: a standard of anesthetic potency. Anesthesiology 1965; 26: 75663[ISI][Medline]
10 Roizen MF, Horrigan RW, Frazer BM. Anesthetic doses blocking adrenergic (stress) and cardiovascular responses to incisionMAC BAR. Anesthesiology 1981; 54: 3908[ISI][Medline]
11 Ishizaki K, Yoon D, Yoshida N, Yamazaki M, Arai K, Fujita T. Intrathecal administration of N-methyl-D-aspartate receptor antagonist reduces the minimum alveolar anaesthetic concentration of isoflurane in rats. Br J Anaesth 1995; 75: 6368
12 Feng J, Kendig JJ. N-methyl-D-aspartate receptors are implicated in hyperresponsiveness following naloxone reversal of alfentanil in isolated rat spinal cord. Neurosci Lett 1995; 189: 12830[CrossRef][ISI][Medline]
13 Guignard B, Coste C, Costes H, et al. Supplementing desfluraneremifentanil anaesthesia with small dose ketamine reduces perioperative opioid analgesic requirements. Anesth Analg 2002; 95: 1038
14 Smith DJ, Pekoe GM, Martin LL, Coalgate B. The interaction of ketamine with the opiate receptor. Life Sci 1980; 26: 78995[CrossRef][ISI][Medline]
15 Husveit O, Maurset A, Oye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 1995; 77: 3559[ISI][Medline]
16 Pekoe GM, Smith DJ. The involvement of opiate and monoaminergic neuronal systems in the analgesia effects of ketamine. Pain 1982; 12: 5773[CrossRef][ISI][Medline]
17 Tung AS, Yaksh TL. Analgesic effect of intrathecal ketamine in the rat. Reg Anesth Pain Med 1981; 6: 914
18 Docquier MA, Lavand'homme P, Collet V, De Kock M. Spinal 2-adrenoceptors are involved in the MACbar sparing effect of systemic clonidine in rats. Anesth Analg 2002: 95: 9359
19 Maruoka Y, Ohno Y, Tanaka H, et al. Selective depression of spinal polysynaptic reflex by the NMDA receptor antagonists in an isolated spinal cord in vivo. Gen. Pharmacol 1997; 29: 6459[CrossRef][Medline]
20 Dickenson AH. Spinal cord pharmacology of pain. Br J Anaesth 1995; 75: 193200
21 Nadeson R, Tucker E, Bajunaki, Goodchild C. Potentiation by ketamine of fentanyl antinociception. I. An experimental study in rats showing that ketamine administered by non-spinal routes targets spinal cord antinociceptive systems. Br J Anaesth 2002; 88: 68591
22 Higuchi S, Tanaka N, Shioiri Y, Otomo S, Aihara H. Two modes of analgesic action of aspirin, and the site of analgesic action of salicylic acid. Int J Tissue React 1986; 8: 32731[ISI][Medline]
23 Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs 1996; 52: 1323[ISI][Medline]
24 Malmberg AB, Yaksh TL. Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. J Pharmacol Exp Ther 1992; 263: 13646[Abstract]
25 Yamamoto T, Nozaki-Taguchi N. Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor. Brain Res 1996; 739, 10410[CrossRef][ISI][Medline]
26 Devoghel JC. Small intrathecal doses of lysine-acetylsalicylate relieve intractable pain in humans. J Int Med Res 1983; 11: 901[ISI][Medline]
27 Moss JT, Baysinger CL, Boswell GW, Sayson S. Possible intraoperative anesthetic-sparing effect of parenteral ketorolac. Ann Pharmacother 1992; 26: 9224[Abstract]
28 Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996; 93: 231721
29 Dildy-Mayfield JE, Adron Harris R. Volatile anesthetic effects at excitatory amino acid receptors in molecular basis of anaesthesia. In: Moody E, Skolnick P, eds Molecular Bases of Anesthesia. Boca Raton, FL: CRC Press, 2001; 23144
|